Pharmasum Therapeutics A/S is looking to treat the large number of Down syndrome patients who develop Alzheimer's disease-like pathology. The company's first-in-class inhibitor could slow cognitive decline in Down syndrome by targeting a kinase that regulates two key pathogenic pathways in AD.

Cancer company Lytix Biopharma A/S spun out Pharmasum this year after screening studies "serendipitously identified small molecules that were surprisingly active and selective for protein kinases that have been implicated in neurological diseases rather than cancer," said Anders Fugelli, CEO of Pharmasum and former head of business development at Lytix.